AAPL 206.655 1.0044% MSFT 384.86 2.7965% NVDA 106.185 3.3833% GOOGL 158.72 2.1693% GOOG 160.73 1.9084% AMZN 185.5673 2.7504% META 530.91 2.0451% AVGO 187.43 5.9465% BRK-A 795500.0 0.8495% BRK-B 530.135 0.6312% LLY 855.05 3.0901% TSLA 255.535 1.9123% TSM 163.78 3.783% V 336.305 0.5787% JPM 243.935 1.2683% UNH 426.3 -0.3879% NVO 62.61 2.137% WMT 95.78 0.8635% LVMUY 113.69 1.6632% XOM 108.77 1.3039%
Last update at 2025-04-24T16:49:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
Tue 11 Mar 25, 11:30 AMBioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
Fri 28 Feb 25, 12:30 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -263.89900M | 7.62M | 15.91M | 9.69M | 6.11M |
| Minority interest | 54.69M | -9.78900M | 1.92M | 2.63M | 2.63M |
| Net income | -213.39100M | 9.59M | 16.41M | 6.85M | -12.20700M |
| Selling general administrative | 33.92M | 255.08M | 193.08M | 198.47M | 191.67M |
| Selling and marketing expenses | 42.90M | - | - | - | - |
| Gross profit | 331.08M | 302.71M | 233.52M | 249.21M | 235.01M |
| Reconciled depreciation | 66.80M | 34.88M | 28.64M | 30.32M | 29.24M |
| Ebit | -35.67600M | 17.72M | 21.24M | 31.19M | 27.14M |
| Ebitda | 31.13M | 52.60M | 54.87M | 62.16M | 56.38M |
| Depreciation and amortization | 66.80M | 34.88M | 33.63M | 30.97M | 29.24M |
| Non operating income net other | - | -3.32900M | - | - | - |
| Operating income | -35.67600M | 17.72M | 21.24M | 31.19M | 25.50M |
| Other operating expenses | 560.74M | 409.85M | 299.36M | 308.37M | 291.81M |
| Interest expense | 25.80M | 1.11M | 9.75M | 21.58M | 19.17M |
| Tax provision | -50.50800M | -1.96600M | 1.19M | 1.58M | 1.66M |
| Interest income | - | - | - | - | - |
| Net interest income | -25.79500M | -1.11200M | -9.75100M | -21.57900M | -19.17100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | 8.16M | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -50.50800M | -1.96600M | 1.19M | 1.58M | 1.66M |
| Total revenue | 512.12M | 430.90M | 321.16M | 340.14M | 319.18M |
| Total operating expenses | 379.70M | 281.65M | 211.72M | 217.44M | 207.64M |
| Cost of revenue | 181.04M | 128.19M | 87.64M | 90.94M | 84.17M |
| Total other income expense net | -228.22300M | -10.10200M | -5.32300M | -21.50400M | -2.08800M |
| Discontinued operations | - | - | - | -1.81500M | -16.65000M |
| Net income from continuing ops | -213.39100M | 9.59M | 14.72M | 8.11M | 4.44M |
| Net income applicable to common shares | - | 19.38M | 4.38M | -0.65900M | -17.98800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 810.91M | 1372.65M | 1225.86M | 494.47M | 472.41M |
| Intangible assets | 482.35M | 1038.72M | 695.19M | 191.65M | 216.51M |
| Earning assets | - | - | - | - | - |
| Other current assets | 16.66M | 18.68M | 27.24M | 7.55M | 6.06M |
| Total liab | 589.79M | 1032.32M | 692.07M | 350.31M | 326.79M |
| Total stockholder equity | 173.59M | 316.58M | 458.92M | 142.24M | 142.98M |
| Deferred long term liab | - | - | 133.52M | - | - |
| Other current liab | 115.81M | 233.41M | 3.56M | 3.93M | 15.62M |
| Common stock | 0.08M | 0.08M | 0.07M | 285.17M | 285.15M |
| Capital stock | 0.08M | 0.08M | 0.07M | 285.17M | 285.15M |
| Retained earnings | -321.53600M | -165.30600M | -6.60200M | -144.53900M | -141.70000M |
| Other liab | - | - | 171.57M | 40.23M | 35.30M |
| Good will | 7.46M | 13.76M | 147.62M | 49.80M | 49.80M |
| Other assets | - | - | 50.48M | 34.34M | - |
| Cash | 36.96M | 31.81M | 43.93M | 86.84M | 64.52M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 175.50M | 304.02M | 180.86M | 122.59M | 89.02M |
| Current deferred revenue | 4.75M | - | 142.35M | 99.24M | 56.96M |
| Net debt | 372.51M | 386.25M | 313.75M | 101.54M | 133.44M |
| Short term debt | 31.91M | 33.06M | 18.04M | 15.00M | 10.00M |
| Short long term debt | 27.85M | 33.06M | 18.04M | 15.00M | 10.00M |
| Short long term debt total | 409.48M | 418.07M | 357.68M | 188.38M | 197.97M |
| Other stockholder equity | 494.25M | 481.92M | 465.27M | 287.09M | 20.41M |
| Property plant equipment | - | - | 22.98M | 21.84M | 19.76M |
| Total current assets | 268.00M | 272.57M | 263.10M | 211.79M | 183.03M |
| Long term investments | - | 2.64M | 29.29M | 19.38M | 3.31M |
| Net tangible assets | - | - | -383.89200M | -267.20900M | -291.32800M |
| Short term investments | - | - | - | 19.38M | - |
| Net receivables | 123.05M | 136.65M | 124.96M | 88.28M | 85.13M |
| Long term debt | 367.00M | 385.01M | 339.64M | 173.38M | 187.97M |
| Inventory | 91.33M | 85.41M | 61.69M | 29.12M | 27.33M |
| Accounts payable | 23.04M | 37.55M | 16.91M | 4.42M | 6.44M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | 74.86M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.79M | -0.11000M | 0.18M | 1.61M | -0.46500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.07M | 285.17M | 285.15M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -6.60200M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3.14M | -154.00100M | 50.00M | 19.38M | 3.31M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 542.91M | 1100.07M | 962.76M | 282.67M | 289.37M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -116.43600M | -13.52000M | -20.50000M | -7.91200M | -6.10100M |
| Change to liabilities | - | 18.21M | 20.51M | 6.65M | 12.15M |
| Total cashflows from investing activities | - | -283.76000M | -20.50000M | -7.91200M | -6.10100M |
| Net borrowings | - | 166.20M | -10.00000M | -1.36600M | -5.25000M |
| Total cash from financing activities | 62.08M | 273.37M | -29.56900M | -10.95100M | -13.25600M |
| Change to operating activities | - | -13.27700M | -0.73300M | -3.88200M | -0.42200M |
| Net income | -213.39100M | 9.59M | 14.72M | 8.11M | 4.44M |
| Change in cash | -67.37600M | 12.37M | 22.32M | 21.75M | 25.67M |
| Begin period cash flow | 99.21M | 86.84M | 64.52M | 42.77M | 17.10M |
| End period cash flow | 31.84M | 99.21M | 86.84M | 64.52M | 42.77M |
| Total cash from operating activities | -13.53700M | 22.99M | 71.80M | 40.71M | 45.19M |
| Issuance of capital stock | 5.82M | 109.41M | - | - | - |
| Depreciation | 66.80M | 34.88M | 28.64M | 30.32M | 29.24M |
| Other cashflows from investing activities | - | -262.87000M | 0.17M | 0.43M | -0.04000M |
| Dividends paid | 0.00000M | -0.36700M | -19.88600M | -9.13700M | 7.85M |
| Change to inventory | -18.61800M | 3.18M | -0.52800M | -1.42700M | 3.26M |
| Change to account receivables | -18.02200M | -20.05200M | -3.94100M | -14.90900M | -12.13000M |
| Sale purchase of stock | - | 277.45M | - | - | - |
| Other cashflows from financing activities | 101.29M | -1.87500M | 49.32M | 197.77M | -0.16000M |
| Change to netincome | - | 11.89M | 18.35M | 21.95M | 31.38M |
| Capital expenditures | 11.52M | 7.37M | 20.67M | 8.34M | 6.06M |
| Change receivables | - | -20.05200M | - | - | - |
| Cash flows other operating | - | -25.12000M | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 12.60M | - | - | - |
| Change in working capital | -14.53200M | -13.27700M | 15.31M | -13.57200M | 2.85M |
| Stock based compensation | 17.59M | -4.51200M | 10.10M | 10.84M | 14.32M |
| Other non cash items | 182.79M | 6.08M | 3.53M | 5.36M | -5.59200M |
| Free cash flow | -25.05700M | 15.62M | 51.13M | 32.37M | 39.13M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BVS Bioventus Inc |
0.22 2.90% | 7.81 | - | 16.45 | 1.31 | 5.13 | 1.99 | 34.58 |
| ABT Abbott Laboratories |
0.09 0.07% | 129.93 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
2.69 0.75% | 359.80 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.47 0.56% | 84.22 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
2.28 2.30% | 101.20 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
4721 Emperor Boulevard, Durham, NC, United States, 27703
| Name | Title | Year Born |
|---|---|---|
| Mr. Kenneth M. Reali | CEO & Director | 1966 |
| Mr. Mark Singleton | Sr. VP, CFO & Principal Accounting Officer | 1969 |
| Mr. Anthony James | VP of Operations and Quality | NA |
| Mr. Miguel O. Beltran-Delgado | Sr. VP of Operations | NA |
| Ms. Alessandraa Pavesio | Sr. VP & Chief Science Officer | 1967 |
| Mr. David Crawford | VP of Investor Relations & Treasurer | NA |
| Mr. Anthony D'Adamio | Sr. VP, Gen. Counsel & Corp. Sec. | 1961 |
| Ms. Katrina J. Church | Sr. VP & Chief Compliance Officer | 1962 |
| Mr. Jeff Welch | VP of Bus. Devel. | NA |
| Mr. Christopher K. Yamamoto | Sr. VP of Corp. Devel. & Strategy | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...